A striking statistical finding emerges from real-world analysis of 60,000 patients with type 2 diabetes: semaglutide users demonstrated significantly lower fracture incidence despite experiencing more weight loss than those receiving other weight-loss medications. The 15% reduction in fracture risk defies traditional clinical expectations.
Conventionally, rapid weight reduction correlates with skeletal mineral density loss and heightened fracture vulnerability—particularly in older and post-menopausal populations. Yet semaglutide users maintained bone integrity despite superior weight outcomes. Comparative analysis showed other GLP-1 agents and SGLT2 inhibitors associated with higher fracture rates relative to semaglutide’s baseline.
This unexpected protective profile, independent of weight loss magnitude, suggests GLP-1 receptor signalling may directly enhance bone formation or inhibit pathological resorption, warranting mechanistic investigation.
Was this article helpful?
